Piperlonguminine is a potential novel therapeutic agent for Alzheimer's disease. Extracellular deposits of A-beta in senile plaques of the cerebral cortex are known to be hallmarks of Alzheimer's disease. Recent studies show that a mix of piperlonguminine and dihydropiperlonguminine significantly inhibit the expression of Amyloid Precursor Protein (APP). The decreased production of the peptide Amyloid-beta (A-beta) in SK-N-SH cells is a beneficial effect to Alzheimer's Disease.
Perperamides, including Piperlonguminine, exhibit promising activity against both Gram-positive and Gram-negative bacteria and Candida species. At experimental levels, Piperlonguminine also shows low toxicity in Vero cells and macrophages. The mechanism of this antimicrobial action is still unknown, however, this potent activity against Bacillus subtilis and Candida tropicalis warrants further investigation.
Piperlonguminine shows in vivo antitumor effects agains sarcoma 180 without showing any significant in vitro cytotoxic effect. In addition, many Piperlonguminine analogs are effective in treating various human cancer cell lines. Many similar spice components have been targeted as potential anticancer solutions, and Piperlonguminie is no exception.
REFERENCES: 1. Hong-Shun, Q., Pei, L., et al. Chinese J. Of Phys. 52(3):160-168,2009. 2. Silva,R.S., Endo E.H., et al. Molecules, 14:1171-1182, 2009. 3. Bezerra, D.P.,Pessoa, C., et al.J.Appl. Toxicol. Jul;28(5):599-607,208;4. Rama Subba Rao, V., Suresh, G.,et al. Med. Chem. Res.21:38-46,2012.